Loading clinical trials...

NOT_YET_RECRUITINGPHASE2

Cannabidiol and Alcohol Use Disorder Phenotypes

Effects of Full-spectrum Cannabidiol on Alcohol Consumption and Alcohol Use Disorder Phenotypes: Implications for Precision Medicine

NCT07279558•University of Colorado, Denver

View on ClinicalTrials.gov

Summary

The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.

Detailed Description

Your participation will include up to five in-person visits over about 13 weeks, including a screening visit, a visit to get your medication, a midpoint visit, an experimental lab session, and a final follow-up visit. You will be assigned to a study medication which you will take daily for 8 weeks while completing daily surveys and weekly virtual check-ins with the research team. During the experimental lab session visit, you will be offered alcohol to drink at the bar lab.

Eligibility

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 21-65
•2. Have used CBD and cannabis at least once in the last year
•3. Regularly drink alcohol
•4. Able to provide informed consent and attend in-person study visits

Exclusion Criteria

•1. Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol
•2. Current use of antiepileptic medication or any psychotropic medication besides antidepressants
•3. Pregnant, nursing, or planning a pregnancy
•4. Medical conditions that contraindicates the use of CBD or alcohol
•5. Current medical conditions that may require intensive care during the study period

Locations (1)

University of Colorado School of Medicine- Anschutz Medical Campus

Aurora, Colorado, United States

Key Dates

Start Date

February 1, 2026

Primary Completion Date

August 31, 2029

Completion Date

August 31, 2029

Last Updated

February 13, 2026

Enrollment

180

ESTIMATED participants

Conditions

Alcohol Use Disorder

Interventions

Full-Spectrum Cannabidiol (CBD)

DRUG

Broad-Spectrum Cannabidiol (CBD)

DRUG

Placebo

DRUG

Contacts

Hollis C Karoly, PhD

CONTACT

303-724-7179 hollis.karoly@cuanschutz.edu

Landon Tomb, M.S.

CONTACT

225-244-3429 landon.tomb@cuanschutz.edu

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

NCT05855668

Alcohol Use DisorderCannabis Use Disorder

View study

RECRUITINGNA

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

NCT07071779

Alcohol Use Disorder (AUD)Cocaine Use Disorder (CUD)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cannabidiol and Alcohol Use Disorder Phenotypes

Inclusion Criteria

Exclusion Criteria

Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD)

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

Anxiety During Abstinence in AUD

Image-guided, Robot Navigated Transcranial Magnetic Stimulation (IR-TMS) for Alcohol Use Disorder (AUD)